Compare MEG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | FTRE |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 829.3M |
| IPO Year | 2020 | 2023 |
| Metric | MEG | FTRE |
|---|---|---|
| Price | $22.14 | $13.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $35.25 | $14.06 |
| AVG Volume (30 Days) | 213.2K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $830,538,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $5.41 | N/A |
| Revenue Next Year | $7.19 | $3.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.26 | 1.00 |
| 52 Week Low | $19.10 | $3.97 |
| 52 Week High | $32.00 | $18.67 |
| Indicator | MEG | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 57.90 |
| Support Level | $20.80 | $8.85 |
| Resistance Level | $23.48 | $18.26 |
| Average True Range (ATR) | 0.79 | 0.78 |
| MACD | 0.13 | -0.17 |
| Stochastic Oscillator | 88.92 | 40.27 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.